Hexaware Technologies enters its Q1 FY 2026-2027 results facing the dual challenge of re-accelerating constant-currency revenue growth while managing significant working capital headwinds. Investors will be closely watching whether a weaker rupee provides a margin buffer and if deal ramp-ups in high-growth verticals like Banking and Healthcare can offset persistent drag from the TPP segment.
| Results date | July 29, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 36,130 Mn |
| Previous quarter PAT | Rs. 3,516 Mn |
| Previous quarter EBITDA margin | 15.8% |
| Market cap | Rs. 33,672.21 Cr |
| CMP | Rs. 551.85 |
The company has scheduled a board meeting for July 29, 2026, to consider the audited financial results.
Hexaware's Q1 performance will be heavily influenced by the rupee's depreciation, which moved from ~93 in early April to ~94.40 by late June, acting as a mechanical tailwind for reported revenue and margins. While the company's Q4 FY2025-26 USD revenue growth of 4.6% trailed its full-year target, management is expected to address whether seasonal Q1 strength and the full integration of SMC Squared and CyberSolve can drive a re-acceleration in constant-currency terms. The margin bridge remains a focal point, with analysts looking for the impact of April-cycle wage hikes and H-1B visa costs to be weighed against the FX benefit and improved utilization of 82.6%. The company must also address the working capital deterioration that saw DSO rise to 75 days in Q4, which contributed to a negative operating cash flow of Rs. 76 Mn. Finally, the sustainability of growth in Banking (+30.3% YoY) and Healthcare (+22.7% YoY) will be tested against the ongoing transition drag in the TPP segment, which declined 17.2% YoY.
Operational and Financial Metrics: Monitoring the underlying demand pulse and cost pressures.
Strategic Execution and M&A: Integration and pipeline updates following recent acquisitions.
Regulatory and Compliance: Tracking legacy impacts and new cost provisions.
Revenue reached Rs. 36,130 Mn in Q4 FY2025-26, representing a 12.6% YoY growth. This performance was supported by strong growth in the Banking and Healthcare verticals, though USD revenue growth of 4.6% for the full year remained below the company's target.
Working capital faced pressure in Q4 FY2025-26 as DSO deteriorated to 75 days, exceeding the guided range of 70–72 days. This increase in receivables contributed to a negative operating cash flow of Rs. 76 Mn for the quarter.
The SMC Squared and CyberSolve acquisitions closed in H2 CY2025 and are now fully integrated into the company's operating results. Management is expected to provide commentary on how these additions are impacting revenue contribution and deal TCV in the current quarter.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now